Insider Buying: ADARx Pharmaceuticals (NASDAQ:ADRX) Director Acquires $1,045,772.00 in Stock

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) Director Erez Chimovits purchased 61,516 shares of the stock in a transaction dated Monday, September 28th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $1,045,772.00. Following the completion of the purchase, the director owned 9,292,025 shares in the company, valued at approximately $157,964,425. This trade represents a 0.67% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

ADARx Pharmaceuticals Trading Down 6.6%

Shares of NASDAQ ADRX opened at $18.25 on Friday. ADARx Pharmaceuticals, Inc. has a 52 week low of $17.84 and a 52 week high of $23.21.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded ADARx Pharmaceuticals to a “hold” rating in a report on Saturday.

ADARx Pharmaceuticals Company Profile

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based medicines for immune-mediated and other serious diseases. The company is headquartered in San Diego, California, and uses proprietary technologies designed to modulate disease-related proteins at the RNA level.

ADARx’s pipeline includes investigational therapies intended to address conditions involving the complement system, coagulation pathways and other biologic mechanisms. Its programs are designed to provide targeted, durable treatment through approaches such as RNA interference and related forms of RNA-based therapeutic intervention.

Founded in 2018, ADARx has advanced its drug candidates through preclinical and clinical development and has pursued regulatory and clinical activities in the United States and other international markets.